FRH-0201 人膽管癌細(xì)胞
Catalogue No.: C507
Product Format: a T25 flask
Culture Properties：貼壁
Complete Growth Medium: 89%H-DMEM+10%FBS+1%雙抗
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Application: Cells and cancer research
NOTE: FOR RESEARCH USE ONLY.

Components

Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne disease with a high fatality rate. The clinical diagnosis criteria mainly rely on white blood cell (WBC) and platelet (PLT), which, however, are of limited usage in identifying atypical SFTS. A multicenter study was performed in two hospitals from 2011 to 2023. SFTS patients were categorized as atypical or typical based on the clinical diagnosis criteria. Clinical progress and outcomes were compared between the two groups. A total of 2876 laboratory-confirmed SFTS patients were included in this study, 90.54% (2604/2876) of whom exhibited both thrombocytopenia and leukopenia and were defined as typical SFTS patients, while 9.46% (272/2876) were defined as atypical SFTS patients. Patients with typical SFTS were more likely to develop complications (adjusted odds ratio [OR]?=?2.09, 95% confidence interval [CI]:1.48-2.92, p?

tumors but also their tumor-initiating capacity in secondary mouse implants. In addition, treated mice demonstrated no apparent toxicity. The specificity of these treatments was demonstrated by the lack of effects owqrved using ITGB4 knockout 4T1 or ITGB4-negative CT26 colon carcinoma cells. Because ITGB4 is expressed by CSCs across a variety of tumor types, these results support immunologic targeting of ITGB4 as a promising